[go: up one dir, main page]

SG11201911841PA - Topical formulations comprising montelukast and combinations with mussel adhesive proteins - Google Patents

Topical formulations comprising montelukast and combinations with mussel adhesive proteins

Info

Publication number
SG11201911841PA
SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA
Authority
SG
Singapore
Prior art keywords
montelukast
combinations
topical formulations
mussel adhesive
adhesive proteins
Prior art date
Application number
SG11201911841PA
Inventor
Bengt Ingemar Samuelsson
Ming Gu
Original Assignee
Jiangyin Mucocare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Mucocare Pharmaceutical Co Ltd filed Critical Jiangyin Mucocare Pharmaceutical Co Ltd
Publication of SG11201911841PA publication Critical patent/SG11201911841PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201911841PA 2017-07-05 2018-07-04 Topical formulations comprising montelukast and combinations with mussel adhesive proteins SG11201911841PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CN2018087058 2018-05-16
PCT/CN2018/094441 WO2019007356A1 (en) 2017-07-05 2018-07-04 Topical formulations comprising montelukast and combinations with mussel adhesive proteins

Publications (1)

Publication Number Publication Date
SG11201911841PA true SG11201911841PA (en) 2020-01-30

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911841PA SG11201911841PA (en) 2017-07-05 2018-07-04 Topical formulations comprising montelukast and combinations with mussel adhesive proteins

Country Status (13)

Country Link
US (3) US11672792B2 (en)
EP (1) EP3648767A4 (en)
JP (1) JP7288404B2 (en)
KR (1) KR102785243B1 (en)
CN (3) CN110312513B (en)
AU (1) AU2018295944B2 (en)
CA (1) CA3068818A1 (en)
MA (1) MA52924A (en)
MX (1) MX2020000029A (en)
MY (1) MY201703A (en)
SG (1) SG11201911841PA (en)
TW (1) TWI874298B (en)
WO (1) WO2019007356A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3648767A4 (en) * 2017-07-05 2021-04-28 Jiangyin Mucocare Pharmaceutical Co., Ltd TOPICAL FORMULATIONS INCLUDING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS
SI3678705T1 (en) 2018-09-14 2023-10-30 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. Conjugates of montelukast and peptides
MA54707A (en) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd NEW FORMULATIONS CONTAINING LEUCOTRIENE RECEPTOR ANTAGONISTS
MX2022003057A (en) * 2019-09-14 2022-06-16 Jiangyin Usun Pharmaceutical Co Ltd New peptides.
CN114929259A (en) * 2019-12-02 2022-08-19 艾缇亚(上海)制药有限公司 Novel multifunctional oligopeptides
CN114929283A (en) * 2019-12-02 2022-08-19 艾缇亚(上海)制药有限公司 Novel conjugates of peptides and polysaccharides
BR112022015199A2 (en) 2020-02-03 2022-10-11 Taro Pharma Ind TOPICAL FORMULATIONS OF MONTELUKAST
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
EP4228641A1 (en) 2020-10-13 2023-08-23 Diomed Developments Limited Gel formulations comprising montelukast
CN114588267A (en) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing amide local anesthetic
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
TW202337464A (en) * 2021-08-06 2023-10-01 大陸商安利提沙(上海)製藥有限公司 New treatment of immunodeficiency disorder
CN116421547A (en) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Preparation of a montelukast sodium cream for external use and its application in inflammatory skin diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213989C (en) * 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
US20030207932A1 (en) 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
ATE529125T1 (en) * 2003-08-07 2011-11-15 Healor Ltd PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ACCELERATING WOUND HEALING
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
CN1961867A (en) 2006-11-16 2007-05-16 徐英权 Granule formulation of montelukast sodium
WO2008106081A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
WO2008105803A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2009137555A1 (en) 2008-05-06 2009-11-12 Schlesinger S Larry Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (en) 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 Leukotriene antagonist and antihistaminics composition
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
CN102895661A (en) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 Application of medicine targeting CysLT1 in preparing medicines for preventing or treating autoimmune diseases
JP6200432B2 (en) 2011-12-26 2017-09-20 エスケー ケミカルズ カンパニー リミテッド Film for oral administration containing montelukast or a pharmaceutically acceptable salt thereof
CN103239450B (en) 2012-02-07 2014-11-26 齐鲁制药有限公司 Rapidly-dissolving and stabile montelukast oral solid preparation and preparation method thereof
EP3308835B1 (en) * 2013-03-13 2020-01-01 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN103655497B (en) 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 A kind of Montelukast Sodium oral disnitegration tablet and preparation method thereof
WO2016021599A1 (en) * 2014-08-04 2016-02-11 日東電工株式会社 Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
CN105769825A (en) 2014-12-24 2016-07-20 广州朗圣药业有限公司 Oral film and preparation method of montelukast sodium
CN105878215A (en) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 Stable montelukast oral rapidly disintegrating film as well as preparation method and application thereof
KR101892340B1 (en) * 2015-03-13 2018-08-27 경희대학교 산학협력단 A method to improve montelukast's bio-availability
CN104784157B (en) 2015-04-04 2018-06-26 齐鲁制药有限公司 A kind of montelukast oral membrane agent of stabilization
WO2017011983A1 (en) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 Uses of mussel adhesive protein in protection of skin and accessory organs of skin
BR112018000953A2 (en) 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research Application of Mussel Mucin Products and Their Inhibition of Skin Inflammation
WO2017147067A1 (en) * 2016-02-22 2017-08-31 Board Of Regents, The University Of Texas System Antimicrobial compositions and uses thereof
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
EP3648767A4 (en) * 2017-07-05 2021-04-28 Jiangyin Mucocare Pharmaceutical Co., Ltd TOPICAL FORMULATIONS INCLUDING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS
JP7742226B2 (en) * 2018-05-28 2025-09-19 ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド New drug use
SI3678705T1 (en) * 2018-09-14 2023-10-30 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. Conjugates of montelukast and peptides
MA54707A (en) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd NEW FORMULATIONS CONTAINING LEUCOTRIENE RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
AU2018295944B2 (en) 2023-12-14
TW201919633A (en) 2019-06-01
KR102785243B1 (en) 2025-03-26
CN110312513A (en) 2019-10-08
MX2020000029A (en) 2020-08-06
KR20200039677A (en) 2020-04-16
CN113491696A (en) 2021-10-12
TWI874298B (en) 2025-03-01
EP3648767A1 (en) 2020-05-13
CN110312513B (en) 2022-07-08
AU2018295944A1 (en) 2020-02-20
MY201703A (en) 2024-03-13
CA3068818A1 (en) 2019-01-10
US20230404992A1 (en) 2023-12-21
MA52924A (en) 2021-04-28
US20250302818A1 (en) 2025-10-02
US20210145819A1 (en) 2021-05-20
JP2020527134A (en) 2020-09-03
CN115300508A (en) 2022-11-08
JP7288404B2 (en) 2023-06-07
US11672792B2 (en) 2023-06-13
EP3648767A4 (en) 2021-04-28
WO2019007356A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
SG11201911841PA (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
EP3638700B8 (en) Proteinaceous heterodimer and use thereof
EP3647338A4 (en) Macromolecular compound and light-emitting element using same
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
EP3369795A4 (en) ADHESIVE COMPOSITION AND THERMOFUSIBLE ADHESIVE
EP3235830A4 (en) Interleukin 15 protein complex and use thereof
EP3271436A4 (en) Hot melt adhesive composition and use thereof
SG11201800578YA (en) Mussel adhesive protein product and application thereof in inhibiting catarrh
EP3255059A4 (en) Antimicrobial peptide wy-21 and use thereof
ZA201904704B (en) Topical cyclosporine-containing formulations and uses thereof
EP3290441A4 (en) RGMa BINDING PROTEIN AND USE THEREOF
EP3688036A4 (en) Proteinaceous heterodimer and use thereof
EP3226844A4 (en) Proteins and protein conjugates with increased hydrophobicity
EP3350276A4 (en) An adhesive composition and an articlemanufactured therefrom
IL268583A (en) Topical formulations and methods
EP3290489A4 (en) Silicone adhesive composition and adhesive tape
EP3489225A4 (en) Vortioxetine analogue and use and preparation thereof
EP3279209A4 (en) Adhesive peptide and use therefor
EP3554944B8 (en) Insect elimination system and use thereof
PL3173452T3 (en) Adhesive strip and its use
EP3604336A4 (en) Anti-emap ii antibody and use thereof
EP3325499A4 (en) Novel peptide and use thereof
EP3209697A4 (en) Fn14-binding proteins and uses thereof
HK40091844A (en) Dual function proteins and pharmaceutical composition comprising same
HK40097160A (en) Anti-tim-3 antibodies and use thereof